• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
              Advocacy & Research for Unlimited Lifespans


Longevity Biotech Startup Success and What Antiaging Success Might Look Like

antiaging future life extension medicine science technology

  • Please log in to reply
No replies to this topic

#1 Engadin

  • Guest
  • 196 posts
  • 561
  • Location:Madrid
  • NO

Posted 02 November 2019 - 09:23 PM






F U L L   T E X T   S O U R C E :   NextBIGFuture





In June 2019 at the Ending Age-Related Diseases 2019, James Peyer of Kronos BioVentures gave a talk about the investment aspects of rejuvenation biotechnology.
He explained the effects of the population pyramid, showing the audience why cures for age-related diseases are such a necessity, and comparing population projections.
One hundred years ago, the three leading causes of death for humanity were influenza, tuberculosis, and pneumonia. Today they are dementias, cancer, and cardiovascular diseases.
The old-age dependency ratio is the number of people 65 and older divided by the number of people younger than 65, the working-age adults 15-64. These ratios are rising dramatically over this century. In 1950, the dependency ratio was 12% in the developed world, and this will be almost 50% by 2100.
By the time people are 75 about 41% of all people have at least two chronic conditions and many of them have more. This is problem with only curing one disease like cancer. We need to massively reduce all diseases as we age to get radical life extension.
If Kronos and James Peyer are correct in forecasting the progress of life extension, then those born in the 1960-1970s with access to the leading edge of life extension will have less than a 30% chance of significant life extension. Those people would always be at the edge of not getting enough life extension if ten years of antiaging occurs by 2050 and 20 years by 2070. The odds would be vastly better for those born in 2000 or later.
He explained the startup ecosystem in biotechnology, drug approval, and IPO prices for nascent biotechnology companies.
About 75% of new drugs come from biotech startups.


Edited by Engadin, 02 November 2019 - 09:25 PM.

Also tagged with one or more of these keywords: antiaging, future, life extension, medicine, science, technology

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users